



RELEASED July 25, 2006

COMMUNIQUÉ

The PMPRB to Hold a Public Hearing into the Price of Concerta

OTTAWA, **July 25, 2006**: The Patented Medicine Prices Review Board will hold a public hearing commencing on December 6, 2006, in the matter of Janssen-Ortho Inc. ("Janssen-Ortho") and the price of the medicine Concerta. A pre-hearing conference will also be held on September 15, 2006.

The purpose of the hearing is to determine whether, under sections 83 and 85 of the *Patent Act*, Janssen-Ortho

- is selling or has sold the medicine known as Concerta in any market in Canada at a price that, in the Board's opinion, is or was excessive; and,
- if so, what order, if any, should be made.

Concerta is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

Persons wishing to intervene in this proceeding are required to apply to the Board for leave to intervene **on or before August 22, 2006**. Such persons should contact the Secretary of the Board for further information on the procedure.

The Notice of Hearing in this matter and the Statement of Allegations of Board Staff are available on the PMPRB Web site under Regulatory; Hearings.

All requests for information should be addressed to the Secretary of the Board.

Sylvie Dupont
Secretary of the Patented Medicine Prices Review Board

Toll-free number: 1 877 861-2350
Direct line: (613) 954-8299
Fax: (613) 952-7626
E-mail: sdupont@pmprb-cepmb.gc.ca
Web site: www.pmprb-cepmb.gc.ca

www.pmprb-cepmb.gc.ca